Search clinical trials for: Dopamine Release

Total 8540 results

Boehringer Ingelheim

Completed

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Janssen Korea, Ltd., Korea

Completed

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia (PANDORA)

Schizophrenia

Korea, Republic of
Janssen-Cilag G.m.b.H

Terminated

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Schizophrenia

Germany
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Johnson & Johnson Taiwan Ltd

Completed

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

Schizophrenia
Johnson & Johnson Taiwan Ltd

Completed

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Schizophrenia
Forest Laboratories
Merz Pharmaceuticals GmbH

Completed

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

Autism

United States
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

Healthy

United States
Janssen-Cilag Turkey

Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Schizophrenia

Turkey
Duke University
National Institute of Mental Health (NIMH)

Completed

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

Attention Deficit Disorder With Hyperactivity

United States
Seoul National University Hospital

Completed

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Parkinson Disease

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Schizophrenia

Poland, Israel, Romania, Germany, Lithuania, Croatia, France
Boston Children's Hospital
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

Epilepsy | Attention Deficit Disorder With Hyperactivity

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

Schizophrenia

Ukraine, United States, Spain, India, Romania, Russian Federation, Slovakia
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
The University of Texas Health Science Center,...
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Autism | Attention Deficit Disorder With Hyperactivity

United States
GlaxoSmithKline

Completed

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

Parkinson Disease

United States
Janssen-Cilag, S.A.

Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (PERFLEX)

Schizophrenia

Colombia, Argentina
Centre for Addiction and Mental Health
Pfizer

Completed

Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Tobacco Use Disorder

Canada
Janssen-Cilag Ltd.,Thailand

Completed

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (PRESENT)

Schizophrenia

Thailand
GlaxoSmithKline

Completed

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Attention Deficit Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

Epilepsy | Schizophrenia
Eli Lilly and Company

Terminated

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents (EMD)

Attention Deficit Hyperactivity Disorder

Netherlands, Sweden, Spain
Chonbuk National University Hospital
AstraZeneca; Sanofi-Synthelabo; Janssen Korea, Ltd., Korea; Korea Otsuka Pharmaceutical...

Completed

Different Safety Profile of Risperidone and Paliperidone Extended-release

Schizophrenia

Korea, Republic of
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
University of Cincinnati
National Institute on Drug Abuse (NIDA); Ortho-McNeil Janssen Scientific Affairs...

Completed

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Smoking | ADHD

United States
Rajesh Pahwa, MD
GlaxoSmithKline

Completed

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Parkinson Disease

United States
AstraZeneca

Completed

Quetiapine Extended Release Depression Symptoms (ExAttitude)

Depression | Schizophrenia

Italy
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients (ESPRIT)

Schizophrenia

China
Novartis Pharmaceuticals

Completed

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Novartis Pharmaceuticals
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy (STRIDE-PD)

Parkinson's Disease

United States, Switzerland, Germany, Finland, Greece, Italy, Spain, United Kingdom, Canada, France, Turkey, Belgium, Sweden, Austria
Hadassah Medical Organization

Unknown

A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.

Tobacco Use Disorder

Israel
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Depressive Disorder, Major

United States
Chonnam National University Hospital
Janssen Korea, Ltd., Korea; Ministry of Health, Republic of Korea

Completed

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Children's Hospital of Philadelphia
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory (CHOP)

Attention Deficit Hyperactivity Disorder

United States
Chi-Un Pae
GlaxoSmithKline

Completed

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features (WellbutrinXL)

Depressive Disorder, Major

Korea, Republic of
Pfizer

Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Pharmacokinetics | Cytochrome P-450 CYP2D6 | CYP3A4 Protein, Human

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Healthy Volunteers

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

Attention Deficit Hyperactivity Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Mood Disorders | Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Schizophrenia | Schizoaffective Disorder

3

Subscribe